Free Trial
NASDAQ:DMAAU

Drugs Made in America Acquisition (DMAAU) Stock Price, News & Analysis

About Drugs Made in America Acquisition Stock (NASDAQ:DMAAU)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive DMAAU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Drugs Made in America Acquisition and its competitors with MarketBeat's FREE daily newsletter.

DMAAU Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

DMAAU Stock Analysis - Frequently Asked Questions

Drugs Made in America Acquisition (DMAAU) raised $500 million in an IPO on the week of October 28th 2024. The company issued 50,000,000 shares at a price of $10.00 per share. EF Hutton acted as the underwriter for the IPO.

Shares of DMAAU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:DMAAU
CIK
N/A
Web
N/A
Phone
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
N/A
Beta
N/A
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NASDAQ:DMAAU) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners